Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seproxetine
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
01
Overview
Seproxetine is a selective serotonin reuptake inhibitor (SSRI) and the S-enantiomer of norfluoxetine, which is the main active metabolite of fluoxetine. It was developed as an antidepressant by Eli Lilly but was never marketed due to concerns about cardiac side effects related to QT interval prolongation. Seproxetine acts primarily by inhibiting the sodium-dependent serotonin transporter (SLC6A4), thereby increasing synaptic serotonin levels. It also inhibits dopamine and noradrenaline transporters and has activity at 5-HT2A and 5-HT2C receptors. Compared to fluoxetine, it is more potent in stimulating neurosteroid synthesis relative to its SSRI activity[1][2][3][4].
- Other names
- seproxetine(S)-norfluoxetineseproxetinaseproxetine hydrochloride
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on seproxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seproxetine.